125 related articles for article (PubMed ID: 35818867)
1. Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery and
Swami D; Mudaliar P; Bichu YS; Kumar Sahu V; Devarajan S; Basu S; Aich J
J Biomol Struct Dyn; 2023; 41(12):5802-5816. PubMed ID: 35818867
[TBL] [Abstract][Full Text] [Related]
2. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
[TBL] [Abstract][Full Text] [Related]
3. Investigation of binding characteristics of ritonavir with calf thymus DNA with the help of spectroscopic techniques and molecular simulation.
Kou SB; Zhou KL; Lin ZY; Lou YY; Wang BL; Shi JH; Liu YX
J Biomol Struct Dyn; 2022 Apr; 40(7):2908-2916. PubMed ID: 33164672
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
[TBL] [Abstract][Full Text] [Related]
9. [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].
Bani-Sadr F; Perré P; Peytavin G; Bernard L; Melchior JC; Perronne C; de Truchis P
Presse Med; 2001 Apr; 30(15):731-5. PubMed ID: 11360738
[TBL] [Abstract][Full Text] [Related]
10. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.
Barillari G; Iovane A; Bacigalupo I; Palladino C; Bellino S; Leone P; Monini P; Ensoli B
AIDS; 2012 May; 26(8):909-19. PubMed ID: 22313963
[TBL] [Abstract][Full Text] [Related]
12. The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children.
Gatti G; Pontali E; Boni S; De Pascalis CR; Bassetti M; Bassetti D
HIV Med; 2002 Apr; 3(2):125-8. PubMed ID: 12010359
[TBL] [Abstract][Full Text] [Related]
13. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
14. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
[TBL] [Abstract][Full Text] [Related]
15. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors.
Gatanaga H; Aizawa S; Kikuchi Y; Tachikawa N; Genka I; Yoshizawa S; Yamamoto Y; Yasuoka A; Oka S
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1493-8. PubMed ID: 10580399
[TBL] [Abstract][Full Text] [Related]
16. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
[TBL] [Abstract][Full Text] [Related]
17. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
Arastéh K; Clumeck N; Pozniak A; Lazzarin A; De Meyer S; Muller H; Peeters M; Rinehart A; Lefebvre E;
AIDS; 2005 Jun; 19(9):943-7. PubMed ID: 15905675
[TBL] [Abstract][Full Text] [Related]
18. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
Reddy YS; Ford SL; Anderson MT; Murray SC; Ng-Cashin J; Johnson MA
Antimicrob Agents Chemother; 2007 Apr; 51(4):1202-8. PubMed ID: 17261626
[TBL] [Abstract][Full Text] [Related]
20. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
